People of Pathology Podcast: Adam Smith – Making AI Accessible For All With Indica Labs
Adam Smith shares his journey from being a HALO® customer to helping lead Indica Labs’ mission of making AI accessible to pathologists everywhere.
Overview:
In this episode of the People of Pathology Podcast, host Dennis Strenk and Adam Smith, Chief Commercial Officer of Indica Labs, discuss:
- Adam’s journey from HALO® customer to CCO at Indica Labs
- How firsthand experience with HALO inspired him to join the company in 2015
- The evolution of Indica Labs: from image analysis software to a full digital pathology ecosystem (HALO, HALO Link, HALO AI, HALO AP®, and HALO AP Dx)
- Customer focus as the foundation for innovation
- How Indica Labs has integrated AI into its products
- The goal of bringing AI and digital pathology to the masses: making tools accessible to all labs, large or small
- Examples of how HALO AI and AI Apps are enhancing pathologists’ efficiency and accuracy
- Indica Labs’ philosophy of augmentation, not replacement
- How strategic partnerships with Leica Biosystems, Lunit, and Visiopharm are expanding AI adoption in clinical and research environments
- The future of computational pathology and global impact through AI-driven diagnostics
HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP® is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition, HALO AP® provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR. WBS-MAR-000015v1
HALO AP Dx (K232833) is FDA-cleared for primary diagnostic use with the Hamamatsu NanoZoomer® S360MD Slide scanner in the USA. In addition, HALO AP Dx provides built-in compliance with FDA 21 CFR Part 11 and HIPAA.